Abstract
Summary
Inhalation preparation is a special dosage form that is administered through the lungs. It can quickly and directly enter the lungs to exert drug effects through local administration, reducing the dosage and improving the efficacy of the drug. This report mainly focuses on inhaled generic drugs market.
The global Inhaled Generic Drugs market size is projected to grow from US$ 603.6 million in 2023 to US$ 877.9 million in 2030; it is expected to grow at a CAGR of 5.5% from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Inhaled Generic Drugs Industry Forecast” looks at past sales and reviews total world Inhaled Generic Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Inhaled Generic Drugs sales for 2024 through 2030. With Inhaled Generic Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Inhaled Generic Drugs industry.
This Insight Report provides a comprehensive analysis of the global Inhaled Generic Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Inhaled Generic Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Inhaled Generic Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Inhaled Generic Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Inhaled Generic Drugs.
Inhaled drug delivery has the advantages of fast onset of action, rapid absorption, and few side effects. From the perspective of global mature markets, inhaled drug delivery is the mainstream treatment drug for respiratory diseases and the competitive landscape is relatively stable. There is great clinical demand in the field of inhaled formulations for asthma and COPD. China's market for asthma and inhaled preparations has broad prospects, and the rise of Chinese pharmaceutical companies is expected to come as China's domestic generic varieties are launched one after another.
This report presents a comprehensive overview, market shares, and growth opportunities of Inhaled Generic Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
DPI
MDI
NEB
Segmentation by application
Asthma
COPD
Inhalation Anesthesia
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GSK
AstraZeneca
Boehringer-Ingelheim
CTTQ
Sphsine
Daphne Pharmaceutical
Jewim Pharmaceutical
CF PharmTech
Xianju Pharmaceutical
Joincare Pharmaceutical
Hengrui Medicine
Purity Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Inhaled Generic Drugs market?
What factors are driving Inhaled Generic Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Inhaled Generic Drugs market opportunities vary by end market size?
How does Inhaled Generic Drugs break out type, application?
The global Inhaled Generic Drugs market size is projected to grow from US$ 603.6 million in 2023 to US$ 877.9 million in 2030; it is expected to grow at a CAGR of 5.5% from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Inhaled Generic Drugs Industry Forecast” looks at past sales and reviews total world Inhaled Generic Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Inhaled Generic Drugs sales for 2024 through 2030. With Inhaled Generic Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Inhaled Generic Drugs industry.
This Insight Report provides a comprehensive analysis of the global Inhaled Generic Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Inhaled Generic Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Inhaled Generic Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Inhaled Generic Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Inhaled Generic Drugs.
Inhaled drug delivery has the advantages of fast onset of action, rapid absorption, and few side effects. From the perspective of global mature markets, inhaled drug delivery is the mainstream treatment drug for respiratory diseases and the competitive landscape is relatively stable. There is great clinical demand in the field of inhaled formulations for asthma and COPD. China's market for asthma and inhaled preparations has broad prospects, and the rise of Chinese pharmaceutical companies is expected to come as China's domestic generic varieties are launched one after another.
This report presents a comprehensive overview, market shares, and growth opportunities of Inhaled Generic Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
DPI
MDI
NEB
Segmentation by application
Asthma
COPD
Inhalation Anesthesia
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GSK
AstraZeneca
Boehringer-Ingelheim
CTTQ
Sphsine
Daphne Pharmaceutical
Jewim Pharmaceutical
CF PharmTech
Xianju Pharmaceutical
Joincare Pharmaceutical
Hengrui Medicine
Purity Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Inhaled Generic Drugs market?
What factors are driving Inhaled Generic Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Inhaled Generic Drugs market opportunities vary by end market size?
How does Inhaled Generic Drugs break out type, application?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Inhaled Generic Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Inhaled Generic Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Inhaled Generic Drugs by Country/Region, 2019, 2023 & 2030
2.2 Inhaled Generic Drugs Segment by Type
2.2.1 DPI
2.2.2 MDI
2.2.3 NEB
2.3 Inhaled Generic Drugs Sales by Type
2.3.1 Global Inhaled Generic Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Inhaled Generic Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Inhaled Generic Drugs Sale Price by Type (2019-2024)
2.4 Inhaled Generic Drugs Segment by Application
2.4.1 Asthma
2.4.2 COPD
2.4.3 Inhalation Anesthesia
2.4.4 Others
2.5 Inhaled Generic Drugs Sales by Application
2.5.1 Global Inhaled Generic Drugs Sale Market Share by Application (2019-2024)
2.5.2 Global Inhaled Generic Drugs Revenue and Market Share by Application (2019-2024)
2.5.3 Global Inhaled Generic Drugs Sale Price by Application (2019-2024)
3 Global Inhaled Generic Drugs by Company
3.1 Global Inhaled Generic Drugs Breakdown Data by Company
3.1.1 Global Inhaled Generic Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Inhaled Generic Drugs Sales Market Share by Company (2019-2024)
3.2 Global Inhaled Generic Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Inhaled Generic Drugs Revenue by Company (2019-2024)
3.2.2 Global Inhaled Generic Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Inhaled Generic Drugs Sale Price by Company
3.4 Key Manufacturers Inhaled Generic Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Inhaled Generic Drugs Product Location Distribution
3.4.2 Players Inhaled Generic Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Inhaled Generic Drugs by Geographic Region
4.1 World Historic Inhaled Generic Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Inhaled Generic Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Inhaled Generic Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Inhaled Generic Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Inhaled Generic Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Inhaled Generic Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Inhaled Generic Drugs Sales Growth
4.4 APAC Inhaled Generic Drugs Sales Growth
4.5 Europe Inhaled Generic Drugs Sales Growth
4.6 Middle East & Africa Inhaled Generic Drugs Sales Growth
5 Americas
5.1 Americas Inhaled Generic Drugs Sales by Country
5.1.1 Americas Inhaled Generic Drugs Sales by Country (2019-2024)
5.1.2 Americas Inhaled Generic Drugs Revenue by Country (2019-2024)
5.2 Americas Inhaled Generic Drugs Sales by Type
5.3 Americas Inhaled Generic Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Inhaled Generic Drugs Sales by Region
6.1.1 APAC Inhaled Generic Drugs Sales by Region (2019-2024)
6.1.2 APAC Inhaled Generic Drugs Revenue by Region (2019-2024)
6.2 APAC Inhaled Generic Drugs Sales by Type
6.3 APAC Inhaled Generic Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Inhaled Generic Drugs by Country
7.1.1 Europe Inhaled Generic Drugs Sales by Country (2019-2024)
7.1.2 Europe Inhaled Generic Drugs Revenue by Country (2019-2024)
7.2 Europe Inhaled Generic Drugs Sales by Type
7.3 Europe Inhaled Generic Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Inhaled Generic Drugs by Country
8.1.1 Middle East & Africa Inhaled Generic Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Inhaled Generic Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Inhaled Generic Drugs Sales by Type
8.3 Middle East & Africa Inhaled Generic Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Inhaled Generic Drugs
10.3 Manufacturing Process Analysis of Inhaled Generic Drugs
10.4 Industry Chain Structure of Inhaled Generic Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Inhaled Generic Drugs Distributors
11.3 Inhaled Generic Drugs Customer
12 World Forecast Review for Inhaled Generic Drugs by Geographic Region
12.1 Global Inhaled Generic Drugs Market Size Forecast by Region
12.1.1 Global Inhaled Generic Drugs Forecast by Region (2025-2030)
12.1.2 Global Inhaled Generic Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Inhaled Generic Drugs Forecast by Type
12.7 Global Inhaled Generic Drugs Forecast by Application
13 Key Players Analysis
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Inhaled Generic Drugs Product Portfolios and Specifications
13.1.3 GSK Inhaled Generic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Inhaled Generic Drugs Product Portfolios and Specifications
13.2.3 AstraZeneca Inhaled Generic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Boehringer-Ingelheim
13.3.1 Boehringer-Ingelheim Company Information
13.3.2 Boehringer-Ingelheim Inhaled Generic Drugs Product Portfolios and Specifications
13.3.3 Boehringer-Ingelheim Inhaled Generic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Boehringer-Ingelheim Main Business Overview
13.3.5 Boehringer-Ingelheim Latest Developments
13.4 CTTQ
13.4.1 CTTQ Company Information
13.4.2 CTTQ Inhaled Generic Drugs Product Portfolios and Specifications
13.4.3 CTTQ Inhaled Generic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 CTTQ Main Business Overview
13.4.5 CTTQ Latest Developments
13.5 Sphsine
13.5.1 Sphsine Company Information
13.5.2 Sphsine Inhaled Generic Drugs Product Portfolios and Specifications
13.5.3 Sphsine Inhaled Generic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Sphsine Main Business Overview
13.5.5 Sphsine Latest Developments
13.6 Daphne Pharmaceutical
13.6.1 Daphne Pharmaceutical Company Information
13.6.2 Daphne Pharmaceutical Inhaled Generic Drugs Product Portfolios and Specifications
13.6.3 Daphne Pharmaceutical Inhaled Generic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Daphne Pharmaceutical Main Business Overview
13.6.5 Daphne Pharmaceutical Latest Developments
13.7 Jewim Pharmaceutical
13.7.1 Jewim Pharmaceutical Company Information
13.7.2 Jewim Pharmaceutical Inhaled Generic Drugs Product Portfolios and Specifications
13.7.3 Jewim Pharmaceutical Inhaled Generic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Jewim Pharmaceutical Main Business Overview
13.7.5 Jewim Pharmaceutical Latest Developments
13.8 CF PharmTech
13.8.1 CF PharmTech Company Information
13.8.2 CF PharmTech Inhaled Generic Drugs Product Portfolios and Specifications
13.8.3 CF PharmTech Inhaled Generic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 CF PharmTech Main Business Overview
13.8.5 CF PharmTech Latest Developments
13.9 Xianju Pharmaceutical
13.9.1 Xianju Pharmaceutical Company Information
13.9.2 Xianju Pharmaceutical Inhaled Generic Drugs Product Portfolios and Specifications
13.9.3 Xianju Pharmaceutical Inhaled Generic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Xianju Pharmaceutical Main Business Overview
13.9.5 Xianju Pharmaceutical Latest Developments
13.10 Joincare Pharmaceutical
13.10.1 Joincare Pharmaceutical Company Information
13.10.2 Joincare Pharmaceutical Inhaled Generic Drugs Product Portfolios and Specifications
13.10.3 Joincare Pharmaceutical Inhaled Generic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Joincare Pharmaceutical Main Business Overview
13.10.5 Joincare Pharmaceutical Latest Developments
13.11 Hengrui Medicine
13.11.1 Hengrui Medicine Company Information
13.11.2 Hengrui Medicine Inhaled Generic Drugs Product Portfolios and Specifications
13.11.3 Hengrui Medicine Inhaled Generic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Hengrui Medicine Main Business Overview
13.11.5 Hengrui Medicine Latest Developments
13.12 Purity Pharmaceutical
13.12.1 Purity Pharmaceutical Company Information
13.12.2 Purity Pharmaceutical Inhaled Generic Drugs Product Portfolios and Specifications
13.12.3 Purity Pharmaceutical Inhaled Generic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Purity Pharmaceutical Main Business Overview
13.12.5 Purity Pharmaceutical Latest Developments
14 Research Findings and Conclusion